Engineering Asymmetric Cu Single-Atom Nanozymes for Inflammation Modulation in Acute Myocardial Infarction

Study Background and Research Question

Acute myocardial infarction (AMI) is a leading cause of mortality worldwide, primarily resulting from a sudden occlusion of coronary arteries that limits oxygen supply to the myocardium. The ensuing cellular injury not only triggers a cascade of inflammatory responses—including infiltration by immune cells and upregulation of cytokines—but also leads to excessive generation of reactive oxygen species (ROS). This oxidative stress drives lipid peroxidation, DNA damage, and protein oxidation, culminating in irreversible cell death pathways such as ferroptosis. Despite advances in reperfusion therapies, persistent inflammation and ROS-mediated damage remain major clinical challenges, often leading to adverse cardiac remodeling and heart failure. Consequently, there is a pressing need for therapies that can simultaneously mitigate oxidative stress and recalibrate immune responses in the context of AMI. The referenced study (Lin et al., ACS Nano) addresses this gap by exploring next-generation nanozymes as both ROS scavengers and immune modulators.

Key Innovation from the Reference Study

The central innovation of the study is the rational design and synthesis of a copper-based single-atom nanozyme (SAN), specifically engineered with an asymmetric coordination environment through bromine (Br) doping—yielding the Cu-BrN3/SAN@M construct. Unlike conventional symmetric Cu-N4 SANs, the inclusion of Br atoms generates a distorted coordination geometry (Cu-BrN3) that fundamentally alters the electronic structure of the copper centers. Density functional theory (DFT) calculations reveal that this structural asymmetry shifts the d-band center of copper closer to the Fermi level, enhancing the adsorption and activation of ROS intermediates. As a result, the nanozyme displays markedly improved catalytic activity toward the decomposition of hydrogen peroxide, hydroxyl radicals, and superoxide anions—key contributors to lipid peroxidation and oxidative tissue injury in AMI.

Methods and Experimental Design Insights

The researchers employed a multi-step synthesis protocol for the asymmetric nanozyme. First, Br-doped Cu single atoms were anchored onto a nitrogen-doped carbon (N–C) matrix, forming the Cu-BrN3/SAN. This core was subsequently coated with a biomimetic membrane via electrostatic self-assembly, generating Cu-BrN3/SAN@M. The study included comprehensive physicochemical characterization (TEM, XPS, and EXAFS analyses) to confirm atomic dispersion and coordination structure. Catalytic activity assays compared ROS scavenging capabilities between the asymmetric and symmetric nanozymes. In vitro, the constructs were assessed for their ability to preserve cardiomyocyte viability under oxidative stress and to influence macrophage polarization and regulatory T cell (Treg) activity. In vivo, a murine AMI model was used to evaluate targeting efficiency, modulation of the inflammatory microenvironment, and reduction of infarct size.

Core Findings and Why They Matter

The Cu-BrN3/SAN@M nanozyme outperformed its symmetric counterpart in several critical aspects:

• Enhanced ROS Scavenging: The asymmetric coordination facilitated efficient decomposition of multiple ROS species, effectively reducing lipid peroxidation and limiting ferroptosis-related cell death.
• Immune Modulation: The nanozyme reprogrammed proinflammatory M1 macrophages toward a reparative M2 phenotype and significantly increased Treg cell activity, contributing to immune homeostasis restoration.
• Cardiac Protection: In vivo, treated animals exhibited improved cardiomyocyte survival, reduced fibrosis, and smaller infarct zones, underscoring both the anti-inflammatory and antioxidant efficacy of the nanozyme (Lin et al.).

Collectively, these findings highlight the therapeutic promise of structure-tailored SANs for integrated management of inflammation and oxidative injury in cardiovascular disease.

Comparison with Existing Internal Articles

Several internal articles have examined the importance of robust lipid peroxidation detection and oxidative stress measurement in translational research. For instance, "BODIPY 581/591 C11: Next-Generation Insights and Strategies" emphasizes the mechanistic value of ratiometric fluorescent probes for quantifying lipid oxidative damage and guiding antioxidant intervention. Likewise, "BODIPY 581/591 C11: Ratiometric Fluorescent Probe for Lipid Peroxidation Detection" details how ratiometric lipid peroxidation detection is now essential for evaluating antioxidant capacity and understanding ferroptosis pathways. The reference study builds on this analytical foundation, leveraging advanced nanozyme design not only to modulate redox biology but also to directly impact immune responses in a disease-relevant model. The synergy between precise oxidative stress quantification (as enabled by probes like BODIPY 581/591 C11) and mechanistic interventions (such as SANs) is underscored by these complementary resources.

Limitations and Transferability

While the asymmetric Cu single-atom nanozyme demonstrates clear advantages in preclinical AMI models, several limitations warrant consideration:

• Translational Barriers: The complexity of nanozyme synthesis and the need for biomimetic coating may pose scalability and reproducibility challenges for clinical translation.
• Long-term Safety: Comprehensive toxicological studies are needed to assess the long-term fate and biocompatibility of such nanomaterials in humans.
• Model-Specific Effects: The observed immune modulation and ROS scavenging were validated in murine models; extrapolation to human AMI or other inflammatory conditions should be approached with caution until further validation is available.

Nevertheless, the study provides a robust template for rationally designing functional nanomaterials that integrate catalytic and immunomodulatory activities in cardiovascular research.

Protocol Parameters

• Cu-BrN3/SAN@M synthesis: Employ Br doping during single-atom copper anchoring on N–C matrices, followed by membrane coating via electrostatic self-assembly (refer to Lin et al. for detailed parameters).
• In vivo AMI induction: Utilize standard murine models of coronary artery ligation for acute infarction studies.
• Oxidative stress measurement: Quantify lipid peroxidation using validated ratiometric fluorescent probes (such as BODIPY 581/591 C11) in live-cell or tissue assays to monitor therapeutic effects.
• Macrophage polarization assessment: Apply flow cytometry and immunostaining to distinguish M1 vs. M2 phenotypes post-treatment.
• Treg activity quantification: Use established markers (e.g., Foxp3) and functional assays to evaluate regulatory T cell responses.

Research Support Resources

For researchers seeking to replicate or extend these findings, robust oxidative stress and lipid peroxidation quantification is essential. BODIPY 581/591 C11 (SKU C8003, APExBIO) is a ratiometric fluorescent probe designed for sensitive detection of lipid peroxidation and assessment of antioxidant capacity in live cells or membranes. Its unique red-to-green emission shift upon oxidation enables quantitative analysis of lipid oxidative stress, making it well-suited for workflows evaluating the efficacy of nanozyme or antioxidant interventions. For assay optimization and best practices, consult scenario-based guides such as "Scenario-Driven Best Practices for BODIPY 581/591 C11" for sample handling, data analysis, and reproducibility considerations.